The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 09, 2018
Filed:
Mar. 16, 2015
Applicant:
Raqualia Pharma Inc., Aichi, JP;
Inventors:
Assignee:
RaQualia Pharma Inc., Aichi, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 491/056 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 409/10 (2006.01); C07D 409/14 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01); C07D 417/10 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 263/52 (2006.01); C07D 491/048 (2006.01); A61K 31/4178 (2006.01); A61K 31/422 (2006.01); A61K 31/435 (2006.01); C07D 235/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/4355 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/501 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/538 (2006.01); C07D 235/02 (2006.01); C07D 413/10 (2006.01);
U.S. Cl.
CPC ...
C07D 491/056 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); C07D 235/02 (2013.01); C07D 235/06 (2013.01); C07D 263/52 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/10 (2013.01); C07D 409/14 (2013.01); C07D 413/06 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 417/10 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01);
Abstract
The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.